Resuscitation in the Trauma Intensive Care Unit: Evolving Strategies, Controversies, and Future Directions

INTRODUCTION

Managing a trauma intensive care unit (ICU) is a highly complex and demanding task. Patients are usually received from the emergency department or operating theater, often in critical condition, and are typically managed with a damage-control approach to surgery and resuscitation. This strategy emphasizes minimal interventions to achieve stabilization and hemorrhage control. Consequently, these patients arrive in the ICU incompletely resuscitated and characteristically acidotic, hypothermic, and coagulopathic.¹ In the trauma ICU, management primarily focuses on restoring physiologic equilibrium, ensuring adequate organ perfusion, and preparing the patients for definitive surgical procedures and/or recovery. The course of management should also be time-sensitive, as it profoundly affects patient outcomes.

This article explores the major controversies and evolving strategies in trauma ICU resuscitation, aiming to provide a comprehensive understanding of best practices and current debates in this challenging domain.

METHODS AND RESULTS

A literature search was performed using PubMed, Google Scholar, Embase, and Cochrane library databases from inception through 2024 to identify reports discussing “trauma resuscitation,” “damage control resuscitation,” “aggressive versus restrictive fluid therapy,” “vasopressor use in hemorrhagic shock,” “crystalloid resuscitation,” “colloid resuscitation,” “physiological targets of resuscitation,” “whole blood and component therapy,” and “hypothermia and coagulopathy.” Reports published in English and the following types of articles were included: Case reports, clinical trials, editorials, narrative reviews, meta-analyses, and systematic reviews. Conference abstracts, animal studies, and trial protocols were excluded.

A total of 147 articles were identified and used in this narrative review. Twenty-seven review articles, 75 clinical trials, 10 observational studies, 3 multicenter studies, 11 editorials, and 21 case reports were included.

PRINCIPLES OF TRAUMA RESUSCITATION

Resuscitation in trauma patients prioritizes five key elements: hemorrhage control, restoration of hemodynamic stability, optimization of oxygen delivery, coagulation balance, and preservation of end-organ perfusion. These elements form the cornerstone of early ICU management.

Hemorrhage control remains paramount, as uncontrolled bleeding is the leading cause of preventable death following trauma. Hemostatic techniques include surgical intervention, angioembolization, and the use of hemostatic dressings and tourniquets in prehospital care. Time to hemorrhage control is strongly associated with survival, and prolonged hypotension significantly increases mortality.

Hemodynamic status is typically assessed using invasive arterial pressure monitoring, dynamic indices of fluid responsiveness e.g. pulse pressure variation (PPV), cardiac output (CO) measurement, and focused bedside echocardiography. Early identification and correction of reversible causes of shock – such as tension pneumothorax, cardiac tamponade, or massive hemothorax – are essential components of resuscitation.

Oxygen delivery and tissue perfusion are influenced by hemoglobin concentration, arterial oxygen saturation, and CO. Strategies that optimize all three components are preferred, including early blood transfusion and appropriate ventilatory adjustments. Serial blood lactate measurement and clearance provide clinically useful surrogates of global tissue perfusion and adequacy of resuscitation. Trauma-induced coagulopathy is a complex interplay of hemodilution, hypothermia, acidosis, and consumption of clotting factors. Early recognition and targeted correction using component therapy, tranexamic acid, and point-of-care testing (e.g., thromboelastography) are integral to contemporary damage-control resuscitation protocols.

CRYSTALLOID RESUSCITATION: AGGRESSIVE VERSUS RESTRICTIVE

Fluid resuscitation in trauma patients has long been a critical component of treatment protocols aimed at restoring circulating volume, normalizing blood pressure and improving oxygen delivery. Historically, aggressive crystalloid administration has been advocated, with the belief that quickly restoring blood volume can repay the oxygen debt, correct acidosis, and replenish extracellular fluid deficits. However, a growing body of evidence indicates that this approach may not always yield the desired outcomes, particularly in cases of uncontrolled hemorrhage.

Large volumes of isotonic crystalloids can dilute clotting factors, reduce colloid oncotic pressure, and cause interstitial edema, especially in the lungs and bowel walls, which can contribute to acute respiratory distress syndrome, abdominal compartment syndrome, and delayed healing of surgical wounds.² As research evolves, it becomes clear that a more nuanced understanding of fluid resuscitation strategies is necessary to improve patient survival rates and minimize complications.

Crystalloids are widely used as initial fluid replacement in patients with bleeding. It is common practice to replace each mL of blood lost with 3 mL of crystalloid.³ The 10^th edition of the Advanced Trauma Life Support (ATLS^®) course recommended initial administration of 1 L crystalloid in adult trauma patients. The latest update i.e. 11^th edition emphasizes starting the resuscitation process with early administration of blood products and a limited volume of crystalloids (250–500 mL) in adults if blood products are not available.^4,5 Restrictive fluid resuscitation emphasizes the use of minimal volumes of fluid until hemorrhage control is achieved. This strategy is a core component of damage-control resuscitation, which includes permissive hypotension, hemostatic resuscitation, and limited crystalloid administration. Permissive hypotension, generally defined as maintaining a systolic blood pressure (SBP) of 80–90 mmHg, aims to reduce further bleeding by avoiding disruption of early clot formation.^6,7 However, this strategy is contraindicated in patients with traumatic brain injury (TBI), spinal cord injury, or chronic hypertension, in whom cerebral and spinal cord perfusion must be maintained.⁸

Randomized controlled trials (RCTs) support permissive hypotension in specific contexts.⁹ The landmark study by Bickell et al. demonstrated improved survival with delayed fluid resuscitation in penetrating torso trauma, while Dutton reported no survival advantage with aggressive resuscitation to normotension with lower blood pressure targets in hemorrhagic shock.^9,10 Yet, systematic reviews continue to highlight the need for individualized strategies. Elderly patients, those with cardiac comorbidities, or prolonged transport times may benefit from more tailored resuscitation thresholds.

Aggressive crystalloid administration may worsen metabolic acidosis, as commonly used fluids such as normal saline or Ringer’s lactate are relatively acidic. In addition, it can lead to electrolyte disturbances, further aggravated by trauma-induced hormonal stress responses and rhabdomyolysis secondary to tissue injury.^5,11

Proponents of aggressive resuscitation contend that rapid crystalloid infusion can effectively restore blood pressure and improve tissue perfusion. They assert that this approach is vital for addressing oxygen debt, promoting acidosis clearance, and correcting extracellular fluid deficits.¹² In theory, normalizing blood pressure rapidly enhances oxygen delivery to tissues, mitigating the risks associated with hypoperfusion. However, this strategy has come under scrutiny as experimental and clinical data suggest that premature or aggressive resuscitation can lead to unintended consequences, including dislodging of soft clots and dilutional coagulopathy. Such effects may eventually translate into higher transfusion requirements and increased mortality, particularly in patients with uncontrolled bleeding. Studies during last two decades have raised significant concerns about the efficacy of aggressive fluid resuscitation. Notably, a 2002 study by Dutton et al. randomized 110 patients with hemorrhagic shock into two groups, targeting different SBP levels. While the aggressive group aimed for an SBP >100 mmHg, the restricted group targeted an SBP of 70 mmHg. No significant difference in survival was observed between the two groups, suggesting that titrated initial fluid therapy to a lower than normal SBP may not compromise patient outcomes.¹³

In a prospective trial conducted by Bickell et al. in 1994, researchers compared immediate and delayed fluid resuscitation in patients with penetrating torso injuries.¹⁰ The study found that patients in the delayed resuscitation group demonstrated improved survival and fewer perioperative complications compared with those who received immediate fluid resuscitation. This pivotal research contributed to a paradigm shift in the perspective on the timing and volume of fluid administration in trauma patients.¹⁰ As the medical community continues to re-evaluate fluid resuscitation strategies, the concept of permissive hypotension has gained traction. This approach involves allowing lower than normal blood pressure levels (except in specific patient populations) to minimize the risks associated with aggressive resuscitation.

Despite the increasing evidence supporting more conservative fluid resuscitation strategies, a significant gap persists. High-quality RCTs adequately powered to define optimal time, volume and targets of fluid resuscitation and definitively determine the most effective approach remain limited. A Cochrane review evaluating early versus delayed and large versus small volume fluid resuscitation in trauma patients concluded that the available evidence to determine superiority of any single approach is insufficient. The review concluded that uncertainty remains regarding the optimal fluid resuscitation strategy in bleeding trauma patients, highlighting the need for further research.^13,14 Similarly, Turner et al. in a cohort of 1,309 hypotensive trauma patients reported no significant difference in mortality between early and delayed fluid resuscitation.¹⁵ These findings underscore the importance of not only focusing on fluid protocols but also expediting transfer to definitive care for hemorrhage control.¹⁵

TYPE OF RESUSCITATION FLUID

Given the complex pathophysiology of trauma, an ideal resuscitative fluid must effectively restore intravascular volume and circulation, limit inflammation, prevent coagulopathy, and minimize end organ injury. Crystalloids remain the most widely accepted fluids for initial resuscitation. Most trauma studies have used 0.9% normal saline. However, concerns such as hyperchloremic metabolic acidosis, acute kidney injury (AKI), and potential adverse outcome have brought balanced salt solution, an isotonic solution with physiological or near-physiological chloride concentrations and a pH similar to human blood, into the spotlight.¹⁶ A large multicenter cluster-randomized multiple-crossover trial including 15,802 critically ill patients demonstrated a modest reduction in mortality, renal replacement therapy, and renal dysfunction with balanced crystalloids compared with 0.9% saline.¹⁷ However, subsequent RCTs and two meta-analyses found no significant differences in mortality, AKI, or hospital length of stay between the two types of fluid. Hence, which crystalloid solution is the best for initial trauma management remains debatable. However, pragmatically, 0.9% normal saline should be avoided in patients with severe acidosis, particularly in the presence of hyperchloremia.¹⁸

Hypotonic solutions, such as Ringer’s lactate or hypo-oncotic albumin, have been associated with worse neurological outcomes and increased mortality in patients with TBI as compared to normal saline, likely due to exacerbation of cerebral edema. Accordingly, such solutions should be avoided in this set of patients.¹⁹ Hypertonic saline has demonstrated decreased inflammatory response and a lower incidence of multiple organ failure and mortality in experimental animal models of hemorrhagic shock.²⁰ However, the recent two meta-analyses failed to demonstrate beneficial effects or significant survival benefits in trauma patients, limiting its routine use as resuscitation fluid.^21,22

Colloid solutions such as albumin, hydroxyethyl starch (HES), dextran, and gelatin have been used for volume expansion because of their theoretical ability to sustain plasma oncotic pressure and reduce total fluid requirements. However, their use in trauma remains controversial. Limitations include high cost, risk of adverse reactions, and the potential to worsen coagulopathy or renal dysfunction. In the context of trauma, where hemostasis is already compromised, colloids may exacerbate coagulopathy through impairment of platelet function and coagulation. A meta-analysis comparing colloids with crystalloids in trauma patients reported increased mortality associated with colloid use. In patients with TBI, subgroup analyses have suggested lower mortality with saline or HES compared with albumin and balanced crystalloids; with saline demonstrating superiority over iso-oncotic albumin.²³ Conversely, a recent meta-analysis on non-trauma surgical patients in need of hypovolemic resuscitation reported that a combination of intravenous fluid therapy with crystalloids and volume replacement with HES as colloid resulted in lower postoperative serum creatinine levels, improved hemodynamic stability, reduced vasopressor requirements, and shorter hospital stay, with no significant differences in renal dysfunction, renal failure, or the need for renal replacement therapy.²⁴ Extrapolation of these findings to trauma patients should be done cautiously, given the distinct pathophysiological milieu of hemorrhagic shock and trauma-induced coagulopathy.

Although current literature provides limited evidence supporting the use of colloids; cautious amounts of small volume of colloids, along with crystalloids, during the initial phase of resuscitation in hemodynamically unstable patients might be beneficial.²⁴ The European guidelines also suggests that colloids may be considered if a combination of crystalloids and vasopressors fails to maintain tissue perfusion.²⁵ This approach may have a context-specific role in low-resource or remote settings where blood and blood products may not be readily available, and patients may have to be transported long distance for definitive care. In such circumstances, it may serve as a temporizing measure to preserve perfusion and stabilize the patient until definitive hemorrhage control or transfusion therapy can be instituted.

The clinical use of plasma as part of component therapy in hemorrhagic shock is well-established; however, its role as a resuscitation fluid remains debatable. Theoretically, it appears to be an ideal resuscitation fluid due to its protein-rich composition and its ability to preserve endothelial and epithelial barrier integrity, as evidenced in a rodent model of hemorrhagic shock, thereby potentially reducing third-space fluid loss and improving intravascular volume. In addition, it contains coagulation factors that may help mitigate trauma-induced coagulopathic deterioration.^26,27 Table 1 summarizes the advantages and disadvantages of various crystalloids and colloids.

WHOLE BLOOD (WB) VERSUS COMPONENT THERAPY

Whole blood (WB) transfusion has re-emerged as a significant option in trauma resuscitation, driven by its successful use in military medicine and increasing civilian evidence. Historically, WB was replaced by component therapy due to logistical and storage constraints. However, recent evidence suggests that WB may offer unique advantages, especially during early resuscitation and massive transfusion.²⁸ WB provides red blood cells (RBCs), plasma, and platelets in physiological proportions, potentially offering better hemostatic properties than when components are transfused separately. Component therapy, while customizable, often delays delivery of critical clotting factors due to variable availability and the need to thaw plasma or obtain platelets. Moreover, the volume burden of multiple transfusions can lead to complications like dilutional coagulopathy. Emerging studies evaluating WB in trauma resuscitation report improved 24-h and 30-day survival, along with reduced overall blood product utilization, compared with component-based strategies.^29,30

Two formulations of WB are currently available: warm fresh WB and low-titer type O WB (LTOWB), a Food and Drug Administration -approved product. LTOWB provides greater oxygen-carrying capacity and improved coagulation efficiency at lower transfusion volumes. Unlike blood components, which necessitates freezing and thawing for storage, LTOWB requires only refrigeration, thereby simplifying storage and logistical processes. However, the cold storage process may compromise its hemostatic properties. LTOWB has recently been introduced in the civilian setting, with encouraging evidence demonstrating reductions in mortality and bleeding complications.^31,32 Nevertheless, WB transfusion is associated with several challenges, including limited availability, the risk of alloimmunization particularly in Rh-negative women of childbearing age and reduced platelet efficacy during cold storage. The storage life of platelets in WB is shorter than that in standalone platelet concentrates, raising concerns regarding platelet functional activity.³²

BLOOD PRODUCT TEMPERATURE IN MASSIVE TRANSFUSION

Massive transfusion – defined variably as transfusion of more than 10 units of RBCs within 24 h or replacement of the total blood volume in 24 h is associated with the risk of hypothermia due to infusion of cold-stored blood products. Hypothermia constitutes a key component of the “lethal triad” in trauma (along with acidosis and coagulopathy) and is independently associated with increased mortality and morbidity.³³ Stored blood products are typically maintained at 1–6°C. When infused rapidly, they can significantly reduce core body temperature, particularly in trauma patients who are already predisposed to hypothermia due to environmental exposure, anesthesia, and shock-induced thermoregulatory dysfunction. Research indicates that up to 66% of trauma patients present with hypothermia on admission. Even a mild decrease in temperature (to 34–35°C) can impair enzymatic activity of coagulation factor and platelet function.³⁴ The physiological consequences of hypothermia are extensive and can adversely impact various organ systems, as summarized in Table 2.

VASOPRESSOR USE IN HEMORRHAGIC SHOCK

The use of vasopressors in trauma resuscitation remains controversial. Although hypotension from hemorrhage is primarily volume-responsive, in some cases, early vasopressor use may be necessary to support organ perfusion. This is particularly relevant in patients with TBI or spinal cord injury, where maintenance of adequate cerebral or spinal perfusion pressure is critical to avoid secondary ischemic injury. In TBI or spinal cord injury, permissive hypotension is contraindicated. Maintenance of adequate perfusion to the brain and spinal cord is paramount. Early initiation of a vasopressor such as norepinephrine may therefore be required to maintain a cerebral perfusion pressure above 60–70 mmHg, along with appropriately titrated volume resuscitation.^35,36 Similarly, early administration of ionotropic agents such as dobutamine or adrenaline is warranted in the presence of cardiac dysfunction secondary to trauma such as myocardial contusion, pericardial effusion, or acute brain injury. Vasopressor support is also recommended in patients demonstrating early organ dysfunction attributable to persistent systemic inflammation and vasoplegia during the post-resuscitation period. Ongoing vasodilatation associated with persistent and prolonged shock, extensive tissue damage and sustained release of proinflammatory mediators, which further exacerbate vasodilation may necessitate vasopressor use even after definitive hemorrhage control has been achieved. Apart from the above mentioned conditions, the use of vasopressors in trauma patients remains controversial, with several studies associating early use of vasopressors with increased mortality.^37,38 The recent European guidelines gave a Grade 1C recommendation for vasopressor use in hemorrhagic shock, stating “If a restricted volume replacement strategy does not achieve the target blood pressure, administration of noradrenaline is recommended in addition to fluids to maintain target arterial pressure.”^25,39 Although vasopressors may offer hemodynamic support in hemorrhagic shock, restoration of intravascular volume with balanced fluids and blood products remains the cornerstone of management.⁴⁰

In a severely bleeding trauma patient, the pathophysiological consequence of acute blood loss has two phases. The initial vasoconstrictive and sympatho-excitatory phase evolves into a sympatho-inhibitory phase characterized by vasodilation, resulting from an exhausted sympathetic nervous system and vascular hyporeactivity due to posttraumatic endotheliopathy. Vasopressor therapy should be used cautiously in the management of traumatic hemorrhagic shock, as it appears counterintuitive to the practice of permissive hypotension. Further clinical trials are required to determine the ideal vasopressor, optimal arterial blood pressure goals, and resuscitation strategies that best benefit critically injured trauma patients.

PHYSIOLOGY-GUIDED AND ENDPOINT-DRIVEN RESUSCITATION

Modern trauma care increasingly relies on goal-directed resuscitation strategies guided by dynamic physiological and biochemical parameters rather than static hemodynamic variables alone. This approach improves precision and personalization of care. Table 3 summarizes the various physiological targets in trauma patients.

Key markers and modalities include:

• Lactate clearance: Elevated blood lactate indicates tissue hypoxia; decreasing levels suggest adequate perfusion

• Base deficit: A base deficit <−2 indicates metabolic acidosis and shock. Serial measurement of this parameter helps guide ongoing resuscitation

• ScvO₂/SvO₂ (Central venous oxygen saturation/mixed venous oxygen saturation): Surrogate markers for the balance between oxygen delivery and consumption. Values <70% suggest inadequate perfusion

• Capillary refill time: A simple bedside test reflecting peripheral perfusion; should normalize with adequate resuscitation

• Point-of-care ultrasound: Assesses cardiac function, inferior vena cava collapsibility, and the presence of pneumothorax, or cardiac tamponade

• Advanced hemodynamic monitoring: PPV, stroke volume variation, or non-invasive CO monitoring help assess fluid responsiveness.

The integration of these parameters into resuscitation pathways enables tailored interventions. For example, fluid boluses can be avoided if dynamic indices indicate nonresponsiveness, thereby reducing the risk of fluid overload.

CONCLUSION

Resuscitation in the trauma ICU has undergone significant evolution, shifting from aggressive, volume-heavy strategies to precision-based, physiology-guided care. Key controversies persist around fluid choice, volume thresholds, vasopressor timing, and use of WB. However, integrating real-time monitoring, individualized targets, and multidisciplinary coordination is leading to better outcomes.

WB is increasingly favored for early hemostatic resuscitation, though larger trials are needed to solidify its role in civilian trauma. Vasopressors remain a double-edged sword – lifesaving in some, while harmful in others – requiring careful patient selection.

Ultimately, trauma resuscitation is about achieving a balance between rapid intervention and strategic restraint. Through continued research, technological integration, and protocol refinement, we move closer to a future of safer, more effective trauma care.